Revenue-based financing versus a merchant cash advance: the contracts differ more than the money does

Put the two agreements side by side and the cash flows often look like cousins. The operative words do not. That gap is where the consequences live.

The economics land in roughly the same place

Both hand you money now against sales you have not made. Both price the deal as a fixed total rather than a rate that accrues. Both take repayment out of receipts. Neither gets cheaper because you finished early, unless a clause says otherwise.

Illustrative only: 60,000 advanced against 78,000 repaid is 18,000 of cost, whether the paper calls the 1.30 a factor rate or a cap multiple, and whether the money leaves daily or weekly. The arithmetic does not read the letterhead.

The language is where they part

Why the label matters even when the dollars are identical

1. Usury. Usury caps apply to loans. A genuine sale of receivables is not a loan, which is exactly why so much of this paper is drafted as a sale.
2. Recharacterisation. Courts asked to treat a purchase as a disguised loan tend to look at whether repayment is truly contingent, whether reconciliation is real and used, and whether there is a fixed maturity. Drafting alone does not settle it. See recharacterization.
3. Insolvency. Whether the funder is a creditor with a claim or the owner of property you already sold changes the shape of any restructuring.
4. Disclosure. As of 2026, several states require commercial financing disclosures that reach sales-based financing as well as loans, including New York's Commercial Finance Disclosure Law under NY Financial Services Law art. 8 and California's regime under SB 1235 with the DFPI's implementing regulations. Coverage depends on the state, the transaction size and who is offering it. Read the current rule rather than the summary in a broker's email.

What the revenue share does to the term, and to the price

On a revenue-based deal, two numbers set everything: the cap multiple, which fixes the total, and the revenue share, which sets how fast it comes back. The second one is not under the funder's control and it is not under yours either.

At $80,000 a month of revenue, $6,400 a month goes across and the deal runs about 21 months. Solving for the annualised rate on those payments gives roughly 35%.

At $140,000 a month, $11,200 goes across, the deal finishes in about 12 months, and the annualised figure is roughly 59%.

Same contract, same $35,000 of cost, and the business that grows pays a materially higher annual price for the money. That is the structural feature of any fixed-total product, and the marketing framing — "you only pay when you earn" — describes the payment, not the price.

Which cuts both ways, and honestly. A business that stalls pays a lower annualised cost and carries the obligation far longer, with the remittance sitting on every month of a bad year. Before signing, run the term at your worst plausible revenue and at your best, and decide whether you can live at both ends.

What is the same in both

The UCC-1 on all assets. The bank-statement underwriting. The daily or weekly debit that hits whether or not the deposit landed. The clause making it an event of default to take additional funding — see stacking — and the practical reality that a second position changes how every existing funder behaves.

The comparison that actually helps

Ignore the product names and compute three numbers: total repayment in dollars, cash actually received after any fee is netted at funding, and a realistic number of months.

Illustrative only: 50,000 approved with a 4% fee netted at funding puts 48,000 in your account. A 1.28 cap on the 50,000 means 64,000 repaid. Against the 48,000 you actually received, that is 16,000 of cost, not the 14,000 the rate sheet implies. Over ten months that is a different animal from the same 16,000 over twenty.

Do that arithmetic on both offers. Then read the reconciliation clause, the guaranty and the default section, which is where the two products stop being interchangeable.